Selection of DFU patients and non-DFU controls

Slides:



Advertisements
Similar presentations
JAMES R. CHRISTINA, DPM DIRECTOR SCIENTIFIC AFFAIRS AMERICAN PODIATRIC MEDICAL ASSOCIATION FOOTCARE AND DIABETES.
Advertisements

Research and analysis by Avalere Health Are Medicare Patients Getting Sicker? December 2012.
Outcomes of screening mammography among women aged 40 to 43 Institute for Clinical Evaluative Sciences Toronto, Canada (2006)
Regression coefficient (b) RESULTS AND DISCUSSION
Table 6.1 Prevalent Medicare fee-for-service patient counts and spending for beneficiaries aged 65 and older, by DM, CHF, and/or CKD, 2014 U.S. Medicare.
Copyright © 2007 American Medical Association. All rights reserved.
Chapter 6: Health Expenditures for Persons with CKD
Volume 1: Chronic Kidney Disease Chapter 5: Acute Kidney Injury
Prediabetes Screening and Monitoring
Among Medicare beneficiaries >65 years old with a index hospitalization at the time of dialysis initiation, use of post-acute SNF care was common. Among.
2018 Annual Data Report Volume 1: Chronic Kidney Disease
A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.
Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases  Mahesh.
Chapter 7: Healthcare Expenditures for Persons with CKD
Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR
Visceral fat area (VFA, cm2), subcutaneous fat area (SFA, cm2), body mass index (BMI, kg/m2) and waist circumference (WC, cm) levels according to the quartiles.
States with the largest percentage of white residents have the highest Medicare quality rankings. Percentage of population that is non-Hispanic white according.
Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.
Changes in weight and body mass index (BMI) associated with quality improvement. Changes in weight and body mass index (BMI) associated with quality improvement.
Inclusion process. Inclusion process. Of 5200 eligible patients, 204 declined participation, 111 had diabetes >400 days before All New Diabetics in Scania.
Previously Uninsured Medicare Beneficiaries with History of Cardiovascular Disease or Diabetes Have Much Higher Self-Reported Hospital Admissions After.
Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.
The correlation between visceral fat area (VFA) and body mass index (BMI) in patients with type 2 diabetes. The correlation between visceral fat area (VFA)
Group differences (DKA vs
The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.
Predicted percentage of home discharge by diabetes group adjusting for all variables listed in the age-centered logistic regression model with examination.
Age-adjusted OR (A) and multivariate-adjusted OR (B) and 95% CI for the presence of retinopathy and albuminuria by quintiles of WBC count in 3,776 patients.
An algorithm depicting the basic approach to the Charcot foot
Mean mesangial area (micron2) across normal controls (normal C), patients with type 2 diabetes and normoalbuminuria (normo), patients with type 2 diabetes.
The incidence of insulin-treated type 1 diabetes in the first 35 years of life. The incidence of insulin-treated type 1 diabetes in the first 35 years.
The concept of immortal time bias is depicted schematically using the cohort study from the Taiwanese National Health Insurance data during 2000–2007:
FMD and PWV of patients with diabetes with (T2DM-SCT) or without (T2DM) SCT and of healthy individuals with (SCT) or without (CONT) SCT. FMD measured at.
A single dose of liraglutide (Lira) (7. 5 μg/kg or 0
Forefoot peak plantar pressure in diabetic patients without and with mild, moderate, and severe peripheral neuropathy. *Severe and moderate neuropathy.
Schematic representation of the natural history of obesity.
Observed RW, modeled, and published trial estimates of HbA1c change from baseline. Observed RW, modeled, and published trial estimates of HbA1c change.
The effect of PAD and infection on outcome of cast treatment
Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.
Mean fasting C-peptide levels (for all subjects [A]) and mean peak C-peptide levels (all subjects [B], adolescents [C], and adults [D])after mixed-meal.
Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.
Relationship between week 24 A1C and week 24 BeAM in the exploratory analysis (A), the main analysis (only patients with A1C >7.0% at week 24 were included.
Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.
Waveform analysis at the popliteal artery in 176 diabetic patients with normal ABI (non-PAD). Waveform analysis at the popliteal artery in 176 diabetic.
Adjusted ORs for pregravid, antepartum, and postpartum factors as predictors of likelihood that a woman will gain weight between 3 and 12 months postpartum.
A total of 173 individuals were positive for GADA, and 16 of these were positive for a second antibody (11 were IA-2A positive, and 6 were ZnT8A positive).
Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.
Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.
Glycemic control and body weight over 52 weeks.
Enrollment, outcomes, and pharmacokinetics.
Percent of medical condition-specific expenditures associated with diabetes. Percent of medical condition-specific expenditures associated with diabetes.
HRs for type 2 diabetes by category of age at menarche in the EPIC-InterAct study. HRs for type 2 diabetes by category of age at menarche in the EPIC-InterAct.
Pooled analysis of association between (nonexclusive) breast-feeding and childhood-onset type 1 diabetes in studies investigating ∼2 weeks (nonexclusive)
Percent binding of cross-reactive antibodies from cross-over studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.
RBP4 and glucose metabolism.
This figure shows the inclusion and exclusion criteria used to derive the final analytic cohort of 2563 persons with diabetes from the initial 4915 persons.
Percent binding of cross-reactive antibodies from parallel studies in insulin-treated patients with type 1 or type 2 diabetes. Percent binding of cross-reactive.
Relationship between time from diagnosis of type 2 diabetes to renal biopsy and the proportion of biopsies with any diabetic nephropathy (DN) and any non-diabetic.
Visualization of prescriptive algorithm: provider dashboard prototype.
A: Typical course of a normal sympathetic vasomotor response as recorded by continuous wave Doppler sonography. A: Typical course of a normal sympathetic.
Plots of average estimated and measured GFR vs
Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.
A: Probability of retinopathy-free survival.
New dialysis starts in the United States by year in patients with and without diagnosis of diabetes. New dialysis starts in the United States by year in.
Sources of health outcomes data used in the SJLIFE study where severity grading criteria of long-term and late-onset health events were applied. Sources.
Mean HbA1c (%) and estimated marginal mean SH rate (per 100 patient-years) adjusted for sex, age-group at diagnosis, and diabetes duration, by time period,
Upper panel: For performance of the 10-g monofilament test, the device is placed perpendicular to the skin, with pressure applied until the monofilament.
WM volume did not show the expected increase in volume with age in children with type 1 diabetes (●), in contrast with HC subjects (▲) who showed the (expected)
Cumulative distributions of A1C and fasting plasma glucose values for the U.S. population aged ≥12 years without diabetes for each survey cycle: 1999–2000,
Cumulative mean numbers of confirmed (plasma glucose ≤3
Few patients with youth-onset type 2 diabetes are available to participate in clinical trials. Few patients with youth-onset type 2 diabetes are available.
Presentation transcript:

Selection of DFU patients and non-DFU controls Selection of DFU patients and non-DFU controls. 1Total patient population includes all beneficiaries with at least one medical claim in years evaluated. 2Patients defined as those having at least two claims with diabetes diagnosis (ICD-9-CM 249.x, 250.x) at any time in their claims history. 3Foot ulcer patients defined as those with at least one claim with foot ulcer diagnosis (ICD-9-CM 707.1x, 707.8x, 707.9x) following a diabetes diagnosis in years evaluated (2007–2010 for Medicare; 2007–2011 for private insurance). 4Index date defined as the most recent DFU diagnosis date meeting all sample selection criteria. 5Index date defined as the date of a random medical claim in years evaluated. Selection of DFU patients and non-DFU controls. 1Total patient population includes all beneficiaries with at least one medical claim in years evaluated. 2Patients defined as those having at least two claims with diabetes diagnosis (ICD-9-CM 249.x, 250.x) at any time in their claims history. 3Foot ulcer patients defined as those with at least one claim with foot ulcer diagnosis (ICD-9-CM 707.1x, 707.8x, 707.9x) following a diabetes diagnosis in years evaluated (2007–2010 for Medicare; 2007–2011 for private insurance). 4Index date defined as the most recent DFU diagnosis date meeting all sample selection criteria. 5Index date defined as the date of a random medical claim in years evaluated. J. Bradford Rice et al. Dia Care 2014;37:651-658 ©2014 by American Diabetes Association